Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
NCT00087763 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 135
Last updated 2006-05-03
Summary
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
Conditions
- Macular Degeneration
Interventions
- DRUG
-
Macugen ™ (pegaptanib sodium injection)
Sponsors & Collaborators
- collaborator INDUSTRY
-
Eyetech Pharmaceuticals
lead INDUSTRY
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- FACTORIAL
Eligibility
- Min Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-03-31
- Completion
- 2006-05-31
More Related Trials
-
Subretinal Macugen® for Neovascular Age-Related Macular Degeneration
NCT00788177 ·Status: UNKNOWN ·Phase: PHASE3
-
Pegaptanib Sodium Compared to Sham Injection in Patients With Recent Vision Loss Due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO)
NCT00088283 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Study Of The Long-Term Effect Of Macugen In Patients With Wet Age-Related Macular Degeneration
NCT01245387 ·Status: COMPLETED
-
Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)
NCT00134667 ·Status: TERMINATED ·Phase: PHASE4
-
A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema
NCT01487044 ·Status: AVAILABLE
-
Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
NCT00324116 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Use Of Pegaptanib In Patients For Subfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
NCT00845273 ·Status: COMPLETED
-
Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium
NCT01573572 ·Status: COMPLETED ·Phase: PHASE4
-
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
NCT00605280 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
NCT01601483 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration
NCT00239928 ·Status: COMPLETED ·Phase: PHASE2
-
A Clinical Trial to Explore Safety and Efficacy of Different Doses of Pegaptanib Sodium, Compared to Sham, in Patients With Wet AMD.
NCT00321997 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinical Trial to Explore the Safety and Efficacy of Three Different Doses of Pegaptanib Sodium in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00312351 ·Status: TERMINATED ·Phase: PHASE4
-
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
NCT00858208 ·Status: COMPLETED
-
A Study to Assess the Safety, Tolerability and Effectiveness of MT-0814 for the Treatment of Age-related Macular Degeneration
NCT03869684 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy, Safety, Tolerability of Pegaptanib Sodium (Macugen) in Filipino Patients With Neovascular Age Related Macular Degeneration.
NCT00820742 ·Status: WITHDRAWN
-
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
NCT00150202 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Macugen Treatment of Macular Edema Due to Branch Retinal Vein Occlusion
NCT00406107 ·Status: COMPLETED ·Phase: PHASE4
-
A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy
NCT01487070 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Macugen(Pegaptanib)on Surgical Outcomes and VEGF Levels in Diabetic Patients With PDR (Diabetic Retinopathy or CSDME (Macular Edema)
NCT00446381 ·Status: COMPLETED ·Phase: NA
-
Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
NCT01486771 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of AdGVPEDF.11D in Neovascular Age-related Macular Degeneration (AMD)
NCT00109499 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Investigate the Effect on Central Macular Thickness of Treatment With MG-O-1002 Eye Drops in Participants Aged Over 45 With Neovascular Age-related Macular Degeneration (nAMD)
NCT05390840 ·Status: RECRUITING ·Phase: PHASE2
-
Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration
NCT02127463 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration
NCT01089517 ·Status: COMPLETED ·Phase: PHASE2